ValueScreener

ValueScreener company report

MBX Biosciences, Inc. Common Stock (MBX)

NASDAQ / Healthcare / Biotechnology

Share price

50.71 USD Market dataClose of Oct 15, 2026

Market capitalisation

2.44B USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2025, filed Mar 12, 2026
Ratios computed
Oct 15, 2026
Filed years
3, FY2023 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on invested capital, after tax

-33.3% Computed

From the FY2025 filing

Read quality

Valuation

Price to book

5.01x Computed

FY2025 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

-4.4% Computed

FY2025 accounts, priced at the latest close

Read cash generation

Revenue and net income, by fiscal year

FY2022 Net income: -26.1M USDFY2023 Net income: -32.6M USDFY2024 Net income: -61.9M USDFY2025 Net income: -87.0M USD
Revenue Net income4 fiscal years; a year whose statement names no SEC filing is market data, and the table in Filings says which.
Named tests met
0 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it good

Return on invested capital was -33.3% in FY2025, in the band labelled "Likely below the cost of capital" (below 8.0%), on lines anchored on Damodaran's cost-of-capital data, suggesting returns below the usual cost of the capital employed.

Today, against the Biotechnology industry (78 companies), -33.3% sits at the 59th percentile; the middle half of that group runs from -124.0% to -4.0%.

Is it safe

Debt to equity was 0.0016 in FY2025, in the band labelled "Conservative" (below 0.50), on lines anchored on Graham's defensive-investor criteria, suggesting a balance sheet that relies little on borrowing.

Today, against the Biotechnology industry (252 companies), 0.0016 sits at the 16th percentile; the middle half of that group runs from 0.01 to 0.29.

Year by year against peers
Whether MBX Biosciences, Inc. Common Stock's current ratio stayed above the median of the Biotechnology industry, year by year. (FY2022 to FY2025, 4 fiscal years of MBX Biosciences, Inc. Common Stock with a comparable figure)
The direction
Which way MBX Biosciences, Inc. Common Stock's current ratio has moved, and how steadily. (FY2022 to FY2025, 4 filed years of MBX Biosciences, Inc. Common Stock)
What could explain it
What in MBX Biosciences, Inc. Common Stock's filed statements could explain the movements. (4 readings drawn from the statement lines MBX Biosciences, Inc. Common Stock filed)
What to check next
What to check next on MBX Biosciences, Inc. Common Stock, and where in its filings. (3 questions for MBX Biosciences, Inc. Common Stock)
In one paragraph
One paragraph on MBX Biosciences, Inc. Common Stock's returns, cash, balance sheet and price. (6 of sixteen figures read for MBX Biosciences, Inc. Common Stock)

These are MBX’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research MBXPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 10-K, filed Mar 12, 2026, accession 0001193125-26-103121.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

MBX Biosciences, Inc. Common Stock: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax-33.3% ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Return on equity-23.6% ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Return on capital employed, pre-tax-26.5% ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Return on assets-22.6% ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Gross margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Operating margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Net margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

MBX Biosciences, Inc. Common Stock: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity0.002 ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Current ratio24.62 ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Quick ratio24.62 ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Interest coverage
Why n/a

No interest expense is filed for this year, so coverage is not computed.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Altman Z-score
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Net debt-373.1M ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Total assets 385.1MTotal liabilities 15.9MShareholders' equity 369.2MOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What MBX Biosciences, Inc. Common Stock owned and owed at the end of fiscal 2025, from the balance sheet it filed (10-K, filed Mar 12, 2026, 0001193125-26-103121).

MBX Biosciences, Inc. Common Stock: balance sheet position
Total assets385.1M FiledFY2025 10-K, filed Mar 12, 2026
Total liabilities15.9M FiledFY2025 10-K, filed Mar 12, 2026
Shareholders' equity369.2M FiledFY2025 10-K, filed Mar 12, 2026
Cash373.7M FiledFY2025 10-K, filed Mar 12, 2026
Total debt596.0K FiledFY2025 10-K, filed Mar 12, 2026
Net debt-373.1M
Current ratio24.62
Debt to equity0.002
  • Interest cover: FY2025: No interest expense is filed for this year, so coverage is not computed.

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

MBX Biosciences, Inc. Common Stock: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
P/E on trailing twelve months
Why n/a

Fewer than twenty trading days carry a meaningful trailing price to earnings ratio, so no range is stated.

n/a ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book5.01x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Price to sales
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Enterprise value to EBIT
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Enterprise value to EBITDA
Why n/m

EBITDA is zero or negative, so a multiple of it is not meaningful.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Price to earnings over growth
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Diluted earnings per share-2.38 USD FiledFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Graham number
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121

We publish no fair value or price target of our own. Value MBX on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for MBX Biosciences, Inc. Common Stock today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

MBX Biosciences, Inc. Common Stock: valuation
Share price50.71 USD
Market capitalisation2.44B USD
Enterprise value to EBITDAn/m
Graham numbern/m
Diluted earnings per share, FY2025-2.38 USD

Price to earnings on trailing twelve months: Fewer than twenty trading days carry a meaningful trailing price to earnings ratio, so no range is stated.

Companies like MBX Biosciences, Inc. Common Stock

  1. Dyne Therapeutics, Inc. (DYN)Market cap 2.85B USD
  2. Enliven Therapeutics, Inc. (ELVN)Market cap 2.88B USD
  3. Disc Medicine, Inc. (IRON)Market cap 2.17B USD
  4. Immunome, Inc. (IMNM)Market cap 2.05B USD
  5. Beam Therapeutics Inc. (BEAM)Market cap 2.55B USD

Same industry (Biotechnology) and size band (Mid, 2B to 10B), nearest in market value and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

MBX Biosciences, Inc. Common Stock: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield-4.4% ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Free cash flow-81.9M USD ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Free cash flow margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Dividend yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
FY2022 Free cash flow: -23.6M USDFY2022 Net income: -26.1M USDFY2023 Free cash flow: -32.1M USDFY2023 Net income: -32.6M USDFY2024 Free cash flow: -55.6M USDFY2024 Net income: -61.9M USDFY2025 Free cash flow: -81.9M USDFY2025 Net income: -87.0M USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

MBX Biosciences, Inc. Common Stock: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
5.01xFY2025Oct 15, 2026
n/aFY2025Oct 15, 2026
n/a Operating profit is zero or negative, so there is no profit for a buyer's price to be a multiple of.
-4.4%FY2025Oct 15, 2026
-33.3%FY2025Mar 12, 2026
n/aFY2025Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
0.002FY2025Mar 12, 2026
24.62FY2025Mar 12, 2026
n/aFY2025Oct 15, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/aFY2025Oct 15, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
n/aFY2025Mar 12, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
n/aFY2025Mar 12, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 3 filed fiscal years on record, FY2023 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

4 fiscal years, FY2022 to FY2025. 3 read from the annual reports MBX Biosciences, Inc. Common Stock filed with the SEC, each naming its filing; the rest from statements that name none, which are market data. Amounts in USD, as reported.

MBX Biosciences, Inc. Common Stock: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY2025n/a-98.1M-87.0M-2.38-81.9Mn/a-23.6%10-K, Mar 12, 20260001193125-26-103121
FY2024n/a-68.2M-61.9M-5.82-55.6Mn/a-24.1%10-K, Mar 17, 20250000950170-25-039838
FY2023n/a-35.3M-32.6M-31.96-32.1Mn/an/m10-K, Mar 17, 20250000950170-25-039838
FY2022n/a-25.2M-26.1M-0.82-23.6Mn/an/mMarket data, supplied Oct 15, 2026accession n/a
  • Revenue: Fewer than two filed years carry revenue.
  • Earnings: Earnings was not positive in both 2022 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Earnings per share was not positive in both 2022 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Free cash flow: Free cash flow was not positive in both 2022 and 2025, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

MBX Biosciences, Inc. Common Stock: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Piotroski F-score
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001193125-26-103121
Named tests met0 of 30 Computed
Beta1.90 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 0 met, 21 not met, 9 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
None of the named tests.
Does not
Defensive investor (Benjamin Graham); Deep value; Large cap, low P/E; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); High returns and growth; High yield, low payout; Dividends and buybacks; Low beta, profitable; ROIC at or above WACC; Near the 52-week low; Two thirds of NCAV (Benjamin Graham); High returns, low debt; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Book or below, low debt (Walter Schloss); Tangible book or below; Cash-flow yield and ROIC; Clean books, high ROIC; Cheapest quarter on P/B (David Dreman)
Not measured
Three forensic scores; Low PEG, low debt (Peter Lynch); Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; Z-score and coverage (Edward Altman); P/E times P/B (Benjamin Graham); Cash-covered dividend; Cheapest quarter on P/E (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(18)
  • Piotroski F-Score: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • EV/EBIT: We do not hold this figure for this company, so there is nothing to show.
  • Altman Z-Score: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Beneish M-Score: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • Rev Growth 5Y: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Gross Margin: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Asset Turnover: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • EV/EBITDA: EBITDA is zero or negative, so a multiple of it is not meaningful.
  • Interest Coverage: No interest expense is filed for this year, so coverage is not computed.
  • Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • P/S Ratio: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by the founder: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 18 figures could not be read on this company, among them Piotroski F-Score, P/E Ratio, EV/EBIT. Each blank in the table above names the rest, with its reason. 9 named tests come back incomplete because of them, which is neither met nor missed.
  • We hold 3 filed fiscal years rather than 10, so the run above is shorter than a full decade and is counted as what it is.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map

Apps

  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy